Survival effects of cyclooxygenase-2 and 12-lipooxygenase in Egyptian women with operable breast cancer

Indian Journal of Cancer

Volumn 46, Issue 1, 2009, Pages 54-60

  Zeeneldin, A A ^a   Mohamed, A M ^a   Abdel, H A ^a   Taha, F M ^a   Goda, I A ^b   Abodeef, W T ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Breast cancer; Cyclo oxygenase; Egypt; Lipo oxygenase; Survival

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; ANTINEOPLASTIC AGENT; PTGS2 PROTEIN, HUMAN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; DISEASE FREE SURVIVAL; EGYPT; FEMALE; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PREMENOPAUSE; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; VISCERAL METASTASIS; BREAST TUMOR; ENZYME IMMUNOASSAY; ENZYMOLOGY; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PAGET NIPPLE DISEASE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARACHIDONATE 12-LIPOXYGENASE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; EGYPT; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 65649128613     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.48597     Document Type: Article

References (44)

1. Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, et al. The global breast cancer burden: Variations in epidemiology and survival. Clin Breast Cancer 2005;6:391-401.
2. Elattar IA, Ali-eldin NH, Moneer MM, Elbasmy AA. Cancer Registry 2002-2003, National Cancer Institute of Egypt. Available from: http://www.nci.edu.eg/lectures/NCI%20registry%202002-03. doc. 2007. p. 46.
3. Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, et al. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess 2006;10:iii-iv, ix-xi, 1-204.
4. Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, et al. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 2003;88:574-8.
5. Park K, Han S, Shin E, Kim HJ, Kim JY. Cox-2 expression on tissue microarray of breast cancer. Eur J Surg Oncol 2006;32:10936-.
6. Wulfing P, Diallo R, Muller C, Wulfing C, Poremba C, Heinecke A, et al. Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 2003;129:375-82.
7. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
8. Ranger GS, Thomas V, Jewell A, Mokbel K. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res 2004;24:2349-51.
9. O'Connor JK, Avent J, Lee RJ, Fischbach J, Gaffney DK. Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys 2004;58: 1034-40.
10. Connolly JM, Rose DP. Enhanced angiogenesis and growth of 12lipoxygenase gene-transfected MCF-7 human breast cancer cells in athymic nude mice. Cancer Lett 1998; 132: 107-12.
11. Ara G, Teicher BA. Cyclooxygenase and lipoxygenase inhibitors in cancer therapy. Prostaglandins Leukot Essent Fatty Acids 1996;54:3-16.
12. Hong SH, Avis I, Vos MD, Martinez A, Treston AM, Mulshine JL. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 1999;59:2223-8.
13. Romano M, Catalano A, Nutini M, D'Urbano E, Crescenzi C, Claria J, et al. 5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J 2001; 15:2326-36.
14. Nie D, Hillman GG, Geddes T, Tang K, Pierson C, Grignon DJ, et al. Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res 1998;58: 4047-51.
15. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991;5:2304-12.
16. Tay A, Squire JA, Goldberg H, Skorecki K. Assignment of the human prostaglandin-endoperoxide synthase 2 (PTGS2) gene to 1q25 by fluorescence in situ hybridization. Genomics 1994;23:718-9.
17. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271: 33157-60.
18. Grosser T, Yusuff S, Cheskis E, Pack MA, FitzGerald GA. Developmental expression of functional cyclooxygenases in zebrafish. Proc Natl Acad Sci USA 2002;99:8418-23.
19. Cha YI, Kim SH, Solnica-Krezel L, Dubois RN. Cyclooxygenase-1 signaling is required for vascular tube formation during development. Dev Biol 2005;282:274-83.
20. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-73.
21. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
22. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
23. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122:518-23.
24. Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M. Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 1980;64: 1061-70.
25. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000;6: 135-8.
26. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006;55: 115-22.
27. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
28. Chen XS, Kurre U, Jenkins NA, Copeland NG, Funk CD. cDNA cloning, expression, mutagenesis of C-terminal isoleucine, genomic structure and chromosomal localizations of murine 12-lipoxygenases. J Biol Chem 1994;269: 13979-87.
29. Rodriguez M, Clare-Salzler M. Eicosanoid imbalance in the NOD mouse is related to a dysregulation in soluble epoxide hydrolase and 15-PGDH expression. Ann N Y Acad Sci 2006;1079: 130-4.
30. Chen M, Remold HG. Opposing roles of PGE2 and LXA4 in the regulation of necrosis of Mycobacterium tuberculosis infected macrophages. Abstract 174. In: j immunol, editor. The American Association of Immunologists; 2007; 2007.
31. Sweeney CJ, Marshall MS, Barnard DS, Heilman DK, Billings SD, Cheng L, et al. Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detect Prev 2002;26:238-44.
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
33. Cox DR. The analysis of binary data. London, UK: Methuen; 1970.
34. Singh-Ranger G, Salhab M,Mokbel K. The role of cyclooxygenase-2 in breast cancer: Review. Breast Cancer Res Treat 2008; 109: 189-98.
35. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 2004;31:22-9.
36. Ranger GS, Jewell A, Thomas V, Mokbel K. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers. J Surg Oncol 2004;88: 100-3.
37. Watanabe O, Shimizu T, Imamura H, Kinoshita J, Utada Y, Okabe T, et al. Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anticancer Res 2003;23:3215-21.
38. LimSC. Role of COX-2, VEGF and cyclinD1 in mammary infiltrating duct carcinoma. Oncol Rep 2003; 10:1241-9.
39. Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis G, Cohen C. COX-2 expression in invasive breast cancer: Correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol 2007; 15:255-9.
40. McCarthy K, Bustin SA, Ogunkolade B, Khalaf S, Laban CA, McVittie CJ, et al. Cyclo-oxygenase-2 (COX-2) mRNA expression and hormone receptor status in breast cancer. Eur J Surg Oncol 2006;32:707-9.
41. Guo GL, Yao ZX, Wu J. The clinical significance of expression of cyclooxygenase-2 gene in breast cancer. Zhonghua Yi Xue Za Zhi 2003;83: 1661-4.
42. Kelly LM, Hill AD, Kennedy S, Connolly EM, Ramanath R, Teh S, et al. Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol 2003;29: 707-10.
43. Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 2003;9:2651-6.
44. Nakopoulou L, Mylona E, Papadaki I, Kapranou A, Giannopoulou I, Markaki S, et al. Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathobiology 2005;72:241-9.